Safety of atorvastatin in the collaborative AtoRvastatin diabetes study (CARDS) by Newman, C, Szarek, M, Demicco, D, Hitman, G, Colhoun, H, Betteridge, D, Durrington, P, Neil, H, Livingston, S, Fuller, J

The safety and tolerability of atorvastatin 10 mg in the Collaborative Atorvastatin Diabetes Study (CARDS). by Newman, C, Szarek, M, Colhoun, H, Betteridge, D, Durrington, P, Hitman, G, Neil, H, Demicco, D, Auster, S, Fuller, J

Erratum: Apolipoproteins, cardiovascular risk and statin response in type 2 diabetes: The Collaborative Atorvastatin Diabetes Study (CARDS) by Charlton-Menys, V, Betteridge, D, Colhoun, H, Fuller, J, France, M, Hitman, G, Livingstone, S, Neil, H, Newman, C, Szarek, M, Demicco, D, Durrington, P

Total soluble and endogenous secretory receptor for advanced glycation end products as predictive biomarkers of coronary heart disease risk in patients with type 2 diabetes: an ana... by Colhoun, H, Betteridge, D, Durrington, P, Hitman, G, Neil, A, Livingstone, S, Charlton-Menys, V, Bao, W, Demicco, D, Preston, G, Deshmukh, H, Tan, K, Fuller, J

The effect of atorvastatin therapy on tumour necrosis factor-α and vascular adhesion molecules in patients with type 2 diabetes mellitus with no prior history of coronary heart dis... by Soedamah-Muthu, S, Charlton-Menys, V, Bao, W, Schalkwijk, C, Da Stehouwer, C, Colhoun, H, Betteridge, D, Durrington, P, Hitman, G, Neil, H, Livingstone, S, Fuller, J, Demicco, D, Preston, G